Background/Aims: The expression of PRAME and its role in hepatocellular carcinoma (HCC) remain unknown. The aim of this study was to examine the functional role of PRAME in HCC development and exploring the molecular mechanism. Methods: We first detected PRAME expression in 96 human HCC tissue samples and correlated with clinicopathological characteristics and prognosis of the patients. We then established stable HCC cell lines with PRAME overexpression and knockdown followed by functional analysis in vitro. Further, we examined the relationship between PRAME and p53 pathway in vitro by using Western blotting. Finally, PRAME expression was detected to evaluate its correlation with p-p53 and p53 pathway related apoptotic proteins in xenograft tumor mouse model using immunohistochemistry. Results: PRAME expression was significantly higher in HCC tissues than in adjacent nontumor tissues and their expression was positively correlated with alpha fetoprotein levels and tumor size. In addition, PRAME expression was associated with AJCC stage and is a potential biomarker of poor prognosis regarding 5-year overall survival in HCC. In vitro studies, we found that PRAME expression was higher in HCC cell lines than in normal hepatic cell line. Inhibited cell proliferation and increased cell apoptosis was observed in PRAME knockdown HCC cells. Futher, increased cell apoptosis was correlated with the proportion of cells in G0/ G1 stage, activated p53 mediated apoptosis, and increased cyclin p21 expression. Xenograft analysis in nude mice also found that PRAME knockdown inhibited tumorigenesis while PRAME overexpression had opposite effect. Conclusions: In HCC, PRAME serves as a potential biomarker for poor prognosis and novel therapeutic target in treating this cancer. PRAME is a
Introduction
Hepatocellular carcinoma (HCC) is one of the most common and lethal malignant tumors in the world wide [1] . The poor prognosis of HCC is related to its resistance to chemotherapy and its high rate and short time of recurrence. HCC is currently the third leading cause of tumor lethality in the world [2] [3] [4] . In the People's Republic of China, HCC is the second leading cause of cancer death in men and third in women [4, 5] . The incidence of liver cancer is also rising rapidly in the United States and in Western countries, as well as in other developed countries [6, 7] . Despite many advances in the treatment of HCC, such as surgical resection, chemotherapy, radiofrequency ablation, and arterial intubation, the prognosis of patients with HCC remains poor, underscoring the need to elucidate the mechanism of HCC and identify prognostic biomarkers.
Preferentially expressed antigen of melanoma (PRAME) is synonymous with MAPE (melanoma antigen preferentially expressed in tumors) and OIP4 (OPA-interacting protein 4), and its expression profile defines it as a tumor-related antigen recognized by autologous cytotoxic T cells against surface antigens [8] . PRAME gene encodes human chromosome 22 (22q11.22) reverse strand, which extends in the region of about 12 kb. It is located within the human immunoglobulin lambda locus [9] , Which contains a large number of V1 gene segments for light chain production during B cell development. It is not expressed or only slightly expressed in normal tissues, except testicles, ovaries, endometrium and adrenal glands [10, 11] . However, high levels of PRAME are reported in malignant cells, such as acute and chronic leukemia, primary and metastatic melanoma, Hodgkin's lymphoma, breast cancer, and head and neck squamous cell carcinoma. In most of these tumors, PRAME acts as a poor prognostic factor [12] [13] [14] [15] [16] [17] . Currently, the physiological function of PRAME is not completely understood. Studies have shown that knockdown of PRAME in tumor cell lines suppresses cell proliferation and increases apoptosis and cytotoxic drug sensitivity [13, 18, 19] .
The expression and function of PRAME in HCC tumorigenesis has not been reported previously. We therefore examined whether PRAME could serve as a biomarker of poor prognosis in HCC and how it functions. In a preliminary study in large HCC tumor specimes, we found that overexpression of PRAME was associated with clinicopathological factors and worse prognosis in Chinese HCC patients. Further studies demonstrated that low levels of PRAME in HCC cells induced apoptosis and decreased proliferation rates by inhibiting the activation of p53 apoptotic signaling and downstream apoptosis-related proteins, such as Bcl2, Bax, Bad, and cleaved PARP. Our results demonstrated that PRAME functions as an independent prognostic biomarker for predicting survival in HCC patients while downregulation of PRAME can inhibit HCC by targeting the p53 apoptotic signaling pathway in vitro and in vivo.
Materials and Methods

Experimental protocol approval
All experimental protocols were approved by the Research Bureau of Nanjing Medical University. All the animal protocols were approved by the IACUC of Nanjing Medical University.
Patients and tissue samples
Cancerous and adjacent tissues of 96 HCC patients who underwent surgery between January 2008 and December 2015 were obtained from the First Affiliated Hospital of Nanjing Medical University. All HCC specimens were collected in accordance with the protocols approved by the Ethics Committee of the Affiliated Hospital of Nanjing Medical University. All patients submitted written informed consents prior to participation. Clinical samples were acquired immediately after the resection of the tumor in the operation room (less than 10 minutes), quick-frozen in liquid nitrogen, and stored at −80°C. None of the patients had a history of exposure to either radiotherapy or chemotherapy prior to surgery or a co-occurring tumor diagnosis. Histological grades were classified as well (grades I-II; n= 59) and poorly (grades III-IV; n= 37) differentiated according to the American Joint Committee on Cancer(AJCC) staging system. The patients were followed up for 1-60 months from the date of the operation. The main clinicopathological features of the patients are shown in Table1.
Antibodies
The antibodies used for western blotting were as follows: rabbit polyclonal anti-PRAME (1:1000; Abcam, Cambridge, United Kingdom), rabbit polyclonal anti-p53 (1:1000; Cell Signaling Technology, USA), rabbit monoclonal anti-GAPDH (1:1000; Cell Signaling Technology). Secondary antibody incubation was performed using horseradish peroxidase-linked IgG (Cell Signaling Technology) at a dilution of1:2000. Rabbit polyclonal anti-P21 antibody (1:1000), rabbit polyclonal anti-PARP(1:1000), rabbit polyclonal anti-cleaved-PARP(1:1000), rabbit polyclonal anti-BAX (1:1000), rabbit polyclonal anti-BAD (1:1000), and rabbit polyclonal anti-BCL2 (1:1000), all from Abcam, were also used. The antibodies used for immunohistochemistry were as follows: rabbit polyclonal anti-PRAME (1:100; Absin Bioscience Inc, Shanghai, China), rabbit polyclonal anti-BAX(1:100;Abcam), rabbit polyclonal anti-BAD(1:100;Abcam), rabbit polyclonal anti-Cleaved-PARP(1:100;Abcam),and rabbit polyclonal anti-Ki67 (1:100; Abcam).
Immunohistochemistry
Fresh tumor tissues were fixed in 4% paraformaldehyde solution and embedded in paraffin wax. The 5μm-thick slices were dewaxed twice in dimethyl benzene for 10 min and rehydrated in graded ethanol. Slices were washed with phosphate buffered saline (PBS, pH 7.4) for 4 min three times. Then, the slides were boiled in 10 mmol/L citrate buffer (pH 6.0) for 3 min to restore antigen. After slow cooling, sections were blocked by immersion in 3% methanolic peroxide for 15 min and incubated with primary antibodies against PRAME, p53,BCL2, BAX, BAD, P21,Ki67, and cleaved-PARP overnight at 4°C, followed by horseradish peroxidase(HRP)-conjugated secondary antibodies. The slides were washed with water and stained with hematoxylin, then dehydrated and mounted in resin mount.
All pathological sections were read by three independent pathologists blinded to the clinical and pathological variables of the patients.
To evaluate the expression of PRAME, p53,BCL2, BAX, BAD, P21,Ki67, and cleaved-PARP, at least six high-power domains in each sample were selected and cytoplasmic and nuclear staining were observed under high magnification.
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In addition, more than 500 cells were examined to determine the average percentage of signal-positive cells. To quantify PRAME expression, the H-score (histochemistry score) was calculated based on the percentage of stained cells x staining intensity. According to the expression of PRAME, patients were divided into two groups, a high expression group (>medium value of all HCC H-scores) and a low expression group (≤medium value of all HCC H-scores).
Cell culture
Five common HCC cell lines (HepG2, Hep3B, MHCC-97H, Huh7, and SMMC-7721) and 293T cells were purchased from the Shanghai Cell Bank of the Chinese Academy of Sciences. These cells were cultured in DMEM high glucose culture medium (Gibco Company, USA) supplemented with 1% penicillin streptomycin (Gibco) and 10% fetal bovine serum (Gibco). Cells were cultured in cell culture plates (Thermo, USA, diameter of 10cm) under a moist atmosphere containing 5% CO2at 37°C.
Plasmid construction and transfection
The plasmids pLV-GFP, 8.91and VSVG were used to pack lentivirus and are preserved in our laboratory. The interference plasmids G248-sh1-PRAME-GFP and G248-sh2PRAME-GFP were synthesized and supplied by the JIKAI gene technology company (Shanghai,China).PLV-PRAME-GFP was synthesized and provided by a genetic technologies company named GENEWIZ(Shanghai, China).
Lentiviral packaging systems including three plasmid DNA solutions (pLV-GFP, pLV-PRAME-GFP,G248-GFP,G248-sh1-PRAME-GFP, G248-sh2-PRAME-GFP 20ug, pLR/VSV-G 6μg, and pCMVΔ8.91 15μg) were mixed, and sterilized ultrapure water was added to reach a total volume of 500μl. Then, 0.5 ml 2× HBS and 50μl calcium chloride (2.5mM/L) were added to the former and gently mixed at room temperature for 25min.The DNA mixture, which was used to transfect 293T cells, was diluted in 5ml of fresh DMEM containing 10% FBS and 1% penicillin/streptomycin before transfection. Seven hours later, the medium containing the DNA mixture was discarded and replaced by 10 ml fresh DMEM. After 24h, transfection efficiency was assessed by fluorescence microscopy. At 48 h after transfection, 293T cell supernatants were collected, centrifuged at 1500rpm at 4°C for 5min, and then filtered with a 0.45μm filter. Before infection, 5mL of supernatant and 50μL (1μg/μL) polybrene were added to a 10cm cell culture plate containing 97H or Huh7 cells. After 5h, 5 ml of fresh DMEM containing 10% FBS were added to every plate. After 24 h, the culture medium was replaced, and 48 h later, the cells expressing GFP were observed under a fluorescence microscope to evaluate the transfection efficiency.
RNA extraction and quantitative real-time PCR
Total RNA was extracted from HCC tissues, precancerous tissues, and cell lines using the TRIzol reagent according to the manufacturer's instructions (TIANGEN, Beijing, China). PrimeScript RT Master Mix kit (Takara, Tokyo, Japan) was used to reverse transcribe RNA. The RNA levels of PRAME were determined by quantitative real-time PCR (qRT-PCR) and calculated using the 2−ΔΔCTmethod, with the CT values normalized using GAPDH as an internal control.
The primers used were as follows: PRAME, sense, 5'-AGCCTTTGACGGGAGACA C-3',and antisense,5'-GAGTTCTTCCGTAAATCCAGCA-3';GAPDH, sense, 5'-GG AGCGAGATCCCTCCAAAAT-3', and antisense, 5'-GGCTGTTGTCATACTTCTCA TGG-3'.qRT-PCR was performed using SYBR Green PCR Master Mix (Takara, Tokyo, Japan)in an ABI Prism 7900HT instrument(Applied Biosystems, CA, USA), according to the instructions of the manufacturer.
Cell proliferation analysis
To study the effect of PRIME on cell proliferation, G248-sh1-PRAME-GFP and G248-sh2-PRAME-GFP were used to interfere with the expression of PRAME in SMMC-7721 cells, and pLV-PRAME-GFP was used to overexpress PRAME in HepG2 cells. Cell proliferation was analyzed using the Cell Counting Kit-8 assay (CCK-8, Dojindo, Japan)according to the manufacturer's instructions. Briefly, cells were seeded in 96-well plates at a density of2 × 10 3 cells/well in 100μLculture medium. After adhesion at 4h,the cells were incubated for an additional 0, 24, 48, and 72 h. At the end of each growing phase, 10μL CCK-8 reagent was added to each well and incubated for another 2 h, and then the light absorbance was measured at 450 nm.
In the colony formation assay, cells were seeded in 6-well plates (1000 cells per well) and cultured for 12 days, with the medium replaced with fresh culture medium every 96 h. After fixation for 10 min with 4% For the EdU assay, cells (2000cells/well) were seeded in 24-well plates and incubated for 16h.Cells were starved in DMEM without FBS for 24 h, and then incubated in DMEM containing 5% FBS. The EdU (5'-ethynyl-2'-deoxyuridine) incorporation assay was performed to quantify cell proliferation u [20] sing the Cell-Light™ EdU DNA Cell Proliferation Kit (Guangzhou Ribobio Co, Ltd, Guangzhou, China) according to the manufacturer's instructions. More than five random fields per well were observed, and IPP 6.0(image pro plus 6.0) was used to calculate the proportion of EdU-positive cells in total cells. IPP is a powerful image processing software that provides in-depth analysis of images and is widely used for 2D, 3D image processing, enhancement and analysis [20, 21] .The experiments were repeated three times, and triplicate wells were used for each condition.
Determination of apoptosis in cells and tissues
Annexin V-PE/7-AADflow cytometric analysis was used to determine cell apoptosis with an Annexin V-FITC Apoptosis Detection Kit (BD Biopharmingen, NJ, USA). G248-GFP, G248-sh1-PRAME-GFP, and G248-sh2-PRAME-GFP transfected SMMC-7721 cells, and pLV-PRAME-GFP, pLV-GFP transfected HepG2 cells in logarithmic phase were subjected to Annexin V-PE/7-AADapoptotic analysis. For this analysis, approximately 3×10 4 cells in logarithmic phase were digested by pancreatic enzymes without EDTA, washed in PBS, and centrifuged at 1500 rpm for 5min at 4°C twice. Cells were then stained with the Annexin V-FITC for 15 min in the dark and analyzed using the BD Biosciences FACS Calibur Flow Cytometer (BD Biosciences, NJ, USA). The tests were repeated three times, and triplicate wells were used for each condition.
Cell cycle analysis
Approximately 5×10 4 cells in logarithmic phase were digested with trypsin, washed in PBS, and centrifuged at 2000 rpm for 5 min at 4°C twice. The cells were then fixed at −20°C in 75% ethanol for 4 h, and analyzed with a cell cycle analysis kit(Keygen, Nangjing, China).Finally, cell cycle distribution was analyzed with a FACScan BD flow cytometer (Dickinson Becton, Jose San, CA, USA) with Cell Quest Pro software and GraphPad Prism(version4.0)software. Experiments were performed with three independent replicates.
Protein extraction and western blotting
Cells were washed in PBS and lysed in RIPA lysis buffer supplemented with PMSF and protease inhibitors (Kaiji company of biology, Nanjing, China). Total protein was quantified using a BCA Protein Assay Kit (Beyotime, Jiangsu, China).Protein lysates (10 µg) were suspended in loading buffer and separated on 10% SDS-polyacrylamide gels and then transferred onto polyvinylidenedifluoride membranes (0.45μm, Millipore, Bedford,MA).The blotted membranes were blocked with trisbuffered saline containing 0.05% Tween 20 (TBST) and 5% fat-free dry milk for 2h at room temperature and incubated overnight with primary antibodies diluted in TBST with 1% bovine serum albumin. After washing with TBST for 15min three times, the membranes were further incubated with HRP-conjugated secondary antibodies for 2h at room temperature. Immuno-complexes were detected with an ECL kit (Thermo, USA) according to the manufacturer's protocol.
Xenografttumor mouse model
All mouse experiments were performed according to the approved guidelines from the IACUC of Nanjing Medical University. Male BALB/c nude mice (7 weeks of age) were subcutaneously injected with G248-sh1-PRAME-GFP, G248-GFP transfected SMMC-7721 cells and pLV-PRAME-GFP, pLV-GFP transfected HepG2 cells (5×10 6 /0.1mL PBS) in separate groups (n=6 per group). Tumor volumes were assessed every 2 days. The tumor-bearing mice were sacrificed 40 days after subcutaneous injection, and the tumors were removed.
Statistical analysis
All results were expressed as the mean ± SD. The Student'st-test was used to analyze significant differences between samples. Histograms were evaluated with GraphPad Prism, version4.0(GraphPad Software, SanDiego, CA, USA). Statistical analyses were performed with Stata 11.0. P<0.05 indicated statistical significance.
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Results
High expression of PRAME in HCC cells
The mRNA expression of PRAME in 96 matched pairs of HCC and adjacent non-tumor tissues was compared by qRT-PCR and normalized to GAPDH. The results showed that PRAME mRNA levels were significantly increased in HCC tissues compared with contiguous non-tumor tissues (P<0.001, Fig. 1A ). In addition, PRAME protein levels were significantly higher in tumor tissues than in adjacent tissues by western blotting (Fig. 1B) . Immunohistochemical analysis showed that the expression of PRAME was significantly higher in cancer tissues than in the corresponding non-cancerous tissues (Fig. 1C) . The expression level of PRAME was significantly higher in all HCC cell lines than in normal L02 hepatocytes (P<0.01, Fig. 1D and Fig. 1E ). Taken together, these results indicated that PRAME is upregulated in HCC tissues and HCC cell lines.
Correlation between clinicopathological variables and PRAME expression in HCC patients
The pathophysiological significance of PRAME expression in relation to the clinical features of tumors was examined. The clinical and pathological data are summarized in Table 1 . The results showed that PRAME expression was significantly correlated with the level of alpha fetoprotein (AFP) (P=0.0031), tumor size (P=0.00858), AJCC stage (P=0.021), metastasis(P=0.007339), tumor invasion(P=0.0008351).PRAME expression was not correlated with other factors, such as age and gender. Analysis of the correlation between clinicopathological characteristics and Ki-67expression showed a significant association between Ki-67expression and the level of AFP (P=0.0013) and AJCC stage (P=0.002272). Ki-67expression was also correlated with other factors such as tumor size (P=0.008721), tumor metastasis (P=0.01563), and tumor invasion (P=0.01522). Spearman's correlation coefficient analysis of HCC tissues showed a remarkable positive correlation between PRAME and Ki-67 expression ( Fig. 2A) . These results indicated that PRAME upregulation might contribute to the evolution of HCC. Prognostic significance of PRAME expression To investigate the association between PRAME expression and patient survival, Kaplan-Meier analysis was performed in the 96 HCC patients with subsequent data. Survival curves showed that HCC patients with high PRAME expression had a shorter overall survival than those with low PRAME expression (Fig. 2B) . At the same time, patients with high Ki-67 expression exhibited poor overall survival (Fig. 2C) . Moreover, univariate analysis of the association between patient survival and clinicopathologic parameters revealed a significant association between survival status and clinicopathologic factors such as AFP (P=0.0140), AJCC stage (P=0.0018), tumor size(P=0.0035), metastasis (P= 0.0138), invasion(P=0.0071), the expression of Ki-67 (P=0.0022), and the expression of PRAME (P=0.024)(Table2). Multivariate analysis showed that AFP (P=0.02), tumor size (P=0.02), AJCC stage(P=0.03), metastasis(P=0.02), invasion(P=0.01), the expression of PRAME (P=0.01), and the expression of Ki-67 (P=0.01) were independent prognostic factors in HCC patients (Table3). These data indicated that PRAME could be a valuable prognostic indicator for the prediction of patient survival.
PRAME regulated cell proliferation
To understand the effect of PRAME on cell proliferation, we established PRAME knockdown and overexpressing HCC cell lines, as shown in Fig. 3A .CCK-8and colony formation assays were performed. TheCCK-8 assay showed a significant reduction of HCC cell proliferation in stable PRAME knockdown SMMC-7721 cell lines compared with the control (Fig. 3C) . The overexpression of PRAME increased HepG2 cell proliferation (Fig. 3C) . In addition, the number of colonies was increased in pLV-PRAME-GFP transfected HepG2 cells than in the control G248-GFP transfected group, and the opposite results were obtained in G248-sh1-PRAME-GFP and G248-sh2-PRAME-GFP transfected SMMC-7721 cells compared with control G248-GFP transfected cells (Fig. 3B) . EdU (5-ethynyl-2'-deoxyuridine) cell proliferation assays suggested that down-regulation of PRAME inhibited the proliferation in SMMC-7721 cells and up-regulation of PRAME had the opposite result in HepG2 cells (Fig.  3D) . These results indicated that PRAME can regulate the proliferation of HCC cell lines.
Inhibition of PRAME expression promoted HCC cells apoptosis and increased the proportion of HCC cells in the G1 phase
Previous studies did not clarify whether PRAME can regulate HCC cell apoptosis. Therefore, we investigated whether PRAME is involved in HCC cell apoptosis regulation. We used flow cytometry to analyze apoptosis. PLV-PRAME-GFP, PLV-GFP transfected groups of HepG2 cells and G248-sh1-PRAME-GFP and G248-sh2-PRAME-GFP, G248-GFP transfected groups of SMMC-7721 cells in logarithmic phase were subjected to Annexin V-PE/7-AAD Meanwhile, G248-sh1-PRAME-GFP and G248-sh2-PRAME-GFP transfected cells showed a higher rate of apoptosis than the G248-GFP group (Fig. 4A and Fig. 4B ).To further elucidate the mechanism by which PRAME regulates apoptosis, we examined the expression of proteins involved in the apoptotic pathway, such as p-p53,Bcl-2, cleaved PARP, Bax, and Bad. As shown in Fig. 4E , the level of activation of p-p53,cleaved PARP, Bax and Bad increased, whereas the level of activation of Bcl-2 and PARP decreased in SMMC-7721 cells transfected with pLV-sh1-PRAME-GFP and pLV-sh2-PRAME-GFP, compared with that in cells transfected with G248-GFP.Meanwhile, the level of activation of p-p53, cleaved PARP, Bax, and Bad decreased, whereas the level of activation of Bcl2 and PARP increased in HepG2 cells transfected with pLV-PRAME-GFP compared with that in cells transfected with pLV-GFP. These results indicated that overexpression of PRAME can reduce HCC cell apoptosis by inhibiting the apoptotic pathway mediated by p-p53and Bcl2.
Cell cycle distribution analysis showed that the proportion of PLV-PRAME-GFP transfected HepG2 cells in the G0/G1 phase was decreased compared with that in the pLV-GFP group, with a concomitant significant increase in the proportion of cells in S and G2/M phases (Fig. 4b) . Cellcycle distribution analysis in SMMC-7721 cells transfected with G248-sh1-PRAME-GFP and G248-sh2-PRAME-GFP showed (Fig. 4C and Fig. 4D ). Mechanistic studies showed that knockdown of PRAME upregulated P21, which induces cell cycle arrest in the G0/G1 phase (Fig. 4D) .
PRAME promoted HCC tumorigenesis
To determine whether PRAME affects tumorigenesis in vivo, HepG2 cells transfected with pLV-PRAME-GFP, pLV-GFP and SMMC-7721 cells transfected with G248-sh1-PRAME-GFP, G248-GFPwere injected subcutaneously into male BALB/c nude mice.
Xenograft tumor volume was lower in the G248-Sh1-PRAME-GFP group than in the G248-GFP group (Fig. 5A, P <0 .001). Tumor growth in the G248-Sh1-PRAME-GFP group was slower than that in the G248-GFP group from the 9 th day (Fig. 5B, P <0 .001). Meanwhile, tumor volume was higher in the pLV-PRAME-GFP group than in the pLV-GFP group (Fig. 7A , P< 0.001).Tumor xenograft growth in the pLV-PRAME-GFP group was faster than that in the pLV-GFP group from the 9 th day (Fig. 5B) . Taken together, these results suggested that knockdown of PRAME suppressed tumor growth in vivo and overexpression of PRAME had the opposite effect. Next,we used immunohistochemistry to determine the expression of PRAME and proliferation, cell cycle, and apoptosis-related proteins (Ki-67, p-p53,p21, Bcl2,cleaved PARP, Bad, and Bax) in xenograft tumor tissues.As shown in Fig. 5C ,knockdown of PRAME inhibited HCC cell proliferation, and induced cell apoptosis and cell cycle arrest. Meanwhile, overexpression of PRAME promoted HCC cell proliferation and inhibited cell apoptosis and cell cycle arrest.
The activation of the p53 apoptotic signaling pathway was also abrogated by knockdown of PRAME in vivo (Fig. 5C) , and the opposite effect was observed in pLV-PRAME-GFP transfected HCC cells compared with control pLV-GFP transfected cells (Fig. 5C ). These data demonstrated that PRAME inhibits p53 apoptotic signaling pathway and promotes HCC tumorigenesis in vivo. 
Discussion
Overexpression of PRAME increases gene hypomethylation in its regulatory regions, which may inhibit tumorigenicity and enhance apoptosis in children with acute leukemia, potentially leading to improved prognosis [22] .PRAME has been reported to function as a repressor of retinoic acid (RA) signaling by interacting with retinoic acid receptors (RARs) and inhibiting the transcription of target genes, such as TRAIL, leading to the inhibition of cell differentiation and apoptosis [18, [23] [24] [25] .However, different results were obtained when PRAME was overexpressed or silenced in cervical cancer cell lines [26] .Thus, further insight is needed into the tissue-specific effects of PRAME on gene regulation and how this is achieved.
The discovery of novel HCC molecular targets associated with the prognosis and development of HCC is a major challenge for clinical practitioners and basic scientists. The role of PRAME in the development and prognosis of HCC has not been reported to date; therefore, we chose PRAME as the target of the study.
Apoptosis mediated by p53 is an important pathway for the removal of cancer-prone cells. However, in many cancers, including HCC, this pathway of apoptosis regulation is usually blocked due to p53 mutation [27, 28] or by p53 inhibitors such as Parc and Mortalin [29, 30] .Cytoplasmic mutant p53 accumulation can also block wild-type p53 tumor suppressor function [31] . The Bcl-2 family of proteins is critical for regulating apoptosis induced by various stimuli [32] . BNIP3, a member of the Bcl-2 family, acts as a pro-apoptotic protein that contributes to hypoxia-induced autophagy and cell death [33] .BNIP3L is a functional homologue of BNIP3 that is activated by the tumor suppressor p53 and contributes to apoptosis under hypoxic conditions [34] . PRAME promotes leukemia cell death in vitro by regulating S100A4/p53 signaling [35] . A microarray study of children's AML focusing on the expression of 300 stress-related genes reported that PRAME upregulation is correlated with the downregulation of proapoptotic genes (CIAP2, AKT3, BAK1, BAX) [36] .
The cyclin-dependent kinase (CDK) inhibitor p21 inhibits several CDK activities leading to cell growth arrest and aging under the control of p53 [37] . In the HeLa cervical carcinoma and K562 chronic myelogenous leukemia cell lines, PRAME down-regulates p21, leading to cell cycle arrest in the G0/G1 phase [38] .Therefore we hypothesized that PRAME could regulate apoptosis and cell cycle progression in HCC by activating or inhibiting p53 and its downstream proteins such as Bcl2 and p21.
In the present study, most of the clinical HCC samples showed higher PRAME expression than that in adjacent non-cancerous tissues. In addition, we found that the expression of PRAME was significantly correlated with level of AFP, tumor size, AJCC stage, tumor invasion, and prognosis. There was a remarkable positive correlation between the expression of PRAME and Ki67 in the 96 pairs of HCC tissues examined using the Spearman's correlation coefficient. Univariate and multivariate analyses indicated that PRAME could be an independent prognostic indicator of patient survival.
We also found that overexpression of PRAME in HepG2 cells accelerated cell growth, decreased the number of cells in the G0/G1 phase of the cell cycle, and suppressed apoptosis, whereas PRAME knockdown in SMMC-7721 cells had the opposite effects. Further investigation indicated that silencing of PRAME induced cell cycle arrest in G0/G1 phase by upregulatingp21.In the present study, PRAME inhibited HCC cells by suppressing p53 mediated pathways to regulate apoptosis-related proteins. In HCC, defects in the p53 pathway are frequently associated with cell proliferation, metastasis, vascular invasion, tumor recurrence, and poor prognosis [39] . Thus, the ability to reactivate mutant p53 or to activate alternative apoptotic pathways offers a feasible therapeutic approach in such cancers.
Our results demonstrated that PRAME might modulate HCC cell viability by inhibiting cell cycle arrest and suppressing cell apoptosis through the inhibition of p53 signaling.
Suppression of thep53 pathway can reduce cell apoptosis and mitochondrial damage by the Bcl2 pathway [40] .
We investigated whether cell cycle and apoptosis-associated proteins downstream of the P53/BCL2 pathway were regulated by PRAME. We found that pro-apoptotic proteins such as cleaved PARP, Bad, Bax and the cell cycle-associated protein p21 were downregulated, whereas the anti-apoptotic protein Bcl-2 was upregulated in the presence of PRAME.
Our mouse xenograft models confirmed that PRAME promoted the growth of subcutaneously implanted tumors and promoted cell apoptosis by inhibiting the p53/Bcl2 signaling pathway. These results were consistent with the results obtained in vitro.
The present study showed for the first time that PRAME expression is higher in HCC tissues than in adjacent tissues. High expression of PRAME was correlated with tumor size, AJCC stage, tumor invasion, Ki67, and poor prognosis, which suggested a prognostic value of PRAME in HCC. In addition, Cox regression analysis demonstrated that PRAME could be an independent prognostic factor for the survival of HCC patients. We found that PRAME reduced cellular apoptosis and cell cycle arrest. Finally, we demonstrated that overexpression of PRAME suppressed cell apoptosis in HCC by inhibiting the p53/Bcl2 signaling pathway in vitro and in vivo. Furthermore, we will study the relationship between the PRAME content in serum of patients with liver cancer and the prognosis of liver cancer. PRAME detection kit for patients with liver cancer will be developed. The downstream signaling pathways downstream of PAME except for P53 will be elucidated and the upstream Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry factors which regulate PRAME will be excavated. New drugs for inteference of PRAME will be developed on the base of our research. In summary, our findings indicated that PRAME may be a biomarker of HCC and a novel potential target for the development of diagnostic and therapeutic strategies for HCC and our research will improve the survival rate and quality of life of patients with liver cancer in the future.
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